Dihydrotachysterol, a synthetic vitamin D analog, was developed in the mid-20th century for the management of hypocalcemia and rickets. Its history is marked by its effectiveness in rapidly correcting calcium and phosphate imbalances, particularly in patients with renal osteodystrophy or impaired vitamin D metabolism. Clinical use highlighted the importance of careful dosing and monitoring of calcium levels to prevent hypercalcemia and other adverse effects. Dihydrotachysterol has been included in various combination therapies for metabolic bone disorders, reflecting its role as a potent vitamin D derivative with both therapeutic efficacy and a need for careful clinical oversight.
BRAND NAMES
Hytakerol – commonly used oral formulation
Rocaltrol-DH – available in some countries for calcium regulation
DHT – generic abbreviation used in clinical settings.
MECHANISM OF ACTION
Dihydrotachysterol is a synthetic vitamin D analog that functions by increasing calcium and phosphate absorption from the intestine and promoting bone mineralization. Unlike natural vitamin D, it does not require renal hydroxylation, making it particularly useful in patients with chronic kidney disease or impaired renal function.
PHARMACOKINETICS
Absorption
Dihydrotachysterol is well absorbed from the gastrointestinal tract following oral administration. Peak plasma concentrations are typically achieved within 2–6 hours after ingestion. Its absorption is not significantly affected by food, although taking it with a small amount of dietary fat may slightly enhance bioavailability due to its lipophilic nature.
Distribution
Dihydrotachysterol has an estimated volume of distribution of approximately 10–15 liters in adults. This moderate distribution reflects its extensive plasma protein binding and tissue uptake in the liver, kidneys, and bones, which are the primary sites of its action for calcium and phosphate regulation.
Metabolism
Dihydrotachysterol is metabolized primarily in the liver through hydroxylation to produce active metabolites that help regulate calcium and phosphate homeostasis. Unlike natural vitamin D, it does not require renal hydroxylation, making it suitable for patients with impaired kidney function.
Elimination
Dihydrotachysterol and its metabolites are primarily excreted via the bile into the feces, with a smaller proportion eliminated in the urine. The elimination half-life is approximately 24–36 hours, which allows for sustained correction of calcium and phosphate levels with relatively infrequent dosing.
PHARMACODYNAMICS
Dihydrotachysterol exerts its effects by increasing intestinal absorption of calcium and phosphate and promoting bone mineralization, thereby correcting hypocalcemia and preventing rickets or osteomalacia. Unlike natural vitamin D, it does not require renal hydroxylation, making it effective in patients with chronic kidney disease or impaired renal function.
ADMINISTRATION
Dihydrotachysterol is typically administered orally, as it is well absorbed from the gastrointestinal tract. The dosage is individualized based on the patient’s serum calcium levels, age, and underlying condition. It is usually given once or twice daily, depending on the severity of hypocalcemia and the patient’s response.
DOSAGE AND STRENGTH
Dihydrotachysterol is administered orally, with dosage individualized according to patient age, serum calcium levels, and clinical condition. Typical adult dosing ranges from 0.25 to 1.0 micrograms per day, divided into one or two doses as needed to maintain normal calcium levels. Pediatric dosing is generally lower and carefully titrated based on weight and response.
DRUG INTERACTIONS
Dihydrotachysterol may interact with drugs that affect calcium balance or vitamin D metabolism. Concomitant use with thiazide diuretics can increase the risk of hypercalcemia, while digitalis may pose a higher risk of cardiac arrhythmias if calcium levels rise. Antacids containing magnesium or aluminum can reduce the absorption of dihydrotachysterol, and corticosteroids may antagonize its effects, lowering calcium absorption.
FOOD INTERACTIONS
Dihydrotachysterol absorption is not significantly affected by food, allowing it to be taken with or without meals. However, because it is lipid-soluble, taking it with a small amount of dietary fat may slightly enhance absorption. Patients should avoid excessive dietary calcium or high-dose vitamin D supplements while on therapy, as this may increase the risk of hypercalcemia.
CONTRAINDICATIONS
Dihydrotachysterol is contraindicated in patients with hypercalcemia or vitamin D toxicity, as further supplementation can worsen calcium overload. It should not be used in individuals with known hypersensitivity to dihydrotachysterol or other vitamin D analogs.
SIDE EFFECTS
Hypercalcemia: nausea, vomiting, constipation, fatigue
Headache
Weakness or lethargy
Cardiovascular effects: arrhythmias
Gastrointestinal effects: anorexia, abdominal pain
Soft tissue calcification with prolonged or excessive use
Hypersensitivity reactions.
OVER DOSAGE
Overdose of dihydrotachysterol can lead to hypercalcemia and hyperphosphatemia, which may present with nausea, vomiting, constipation, polyuria, dehydration, weakness, and lethargy. Severe cases can cause cardiac arrhythmias, hypertension, confusion, and soft tissue or vascular calcification.
TOXICITY
Toxicity from dihydrotachysterol primarily results from excessive calcium and phosphate levels in the blood. Clinical manifestations include nausea, vomiting, constipation, polyuria, dehydration, weakness, and lethargy, with severe cases potentially causing cardiac arrhythmias, hypertension, and neurological symptoms. Chronic or repeated overuse can lead to soft tissue and vascular calcification, which may be irreversible.
